ATA-200 / Atamyo Therap - LARVOL DELTA

Impact of Aortic Valve Calcification on Functional Valve Area and Cardiac Structure and Function in a Phase 2 Trial of Ataciguat (AHA 2025) - P2 | "ATA may have other favorable effects on ventricular, valvular, and/or vascular pathophysiology relevant to patients with CAVS.Hypothesis:We hypothesized that slowing the rate of AVC deposition is associated with improvements in valvular compliance and in measures of cardiac structure and function.A phase 2 study randomized patients with moderate CAVS 1:1 to receive ATA 200 mg/day or placebo for up to 12 months (NCT02481258). These data suggest that slowing the rate of AVC deposition with ATA may result in improvements in CO through improved myocardial function and valvular compliance. Larger controlled trials are needed to assess such favorable myocardial/valvular effects that may help to preserve functional capacity and slow progression to HF."

P2 data • Cardiovascular • Congestive Heart Failure • Heart Failure

ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5 (clinicaltrials.gov) - P1/2 | N=6 | Recruiting | Sponsor: Atamyo Therapeutics | Trial completion date: Jan 2032 ➔ Jan 2031 | Trial primary completion date: Jul 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • Gene Therapies

ATA-200 Dose-escalation Gene Therapy Trial in Patients with LGMDR5 (clinicaltrials.gov) - P1/2 | N=6 | Recruiting | Sponsor: Atamyo Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Gene Therapies

ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5 (clinicaltrials.gov) - P1/2 | N=6 | Not yet recruiting | Sponsor: Atamyo Therapeutics | Trial completion date: Jun 2030 ➔ Dec 2031 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Gene therapy • Trial completion date • Trial primary completion date • Viral vector • Gene Therapies

ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5 (clinicaltrials.gov) - P1/2 | N=6 | Not yet recruiting | Sponsor: Atamyo Therapeutics | Initiation date: Jan 2024 ➔ May 2024

Gene therapy • Trial initiation date • Viral vector • Gene Therapies

ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5 (clinicaltrials.gov) - P1/2 | N=6 | Not yet recruiting | Sponsor: Atamyo Therapeutics

Gene therapy • New P1/2 trial • Viral vector • Gene Therapies • Muscular Dystrophy